Life Sciences
Top stories summarized by our editors
4/19/2018

A round of Series A financing brought in about $24.5 million for Italy-based Medical Microinstruments. The proceeds will be used for advancing the development of the company's teleoperated robotic platform for microsurgery, finalizing product and clinical development, securing CE mark approval and launching its product in Europe.

Full Story:
FinSMEs
4/19/2018

A round of mixed financing involving one unnamed investor has pulled in $13 million for Marlborough, Mass.-based CardioFocus, an SEC filing showed. The company, which makes the HeartLight direct-visualization ablation device for atrial fibrillation treatment, will use $2.6 million of the proceeds for sales commissions and finder's fees and is still looking to raise $8 million in the round.

Full Story:
MassDevice (Boston)
4/19/2018

Retrofit, a weight management and disease prevention program developer, was acquired by Livongo Health for undisclosed terms -- a move that complements Livongo's diabetes and hypertension programs. Retrofit's Diabetes Prevention program is expected to be released by Livongo as Livongo DPP powered by Retrofit.

More Summaries:
Livongo Health
4/19/2018

A Global Market Insights report predicts the worldwide market for computed tomography scanners will reach more than $7 billion by 2024, up from $4.7 billion in 2016, because of the growing demand for minimally invasive diagnostic products and the increasing number of chronic disease cases. Canon Medical Systems, Hitachi Medical, Koninklijke Philips, Samsung, Siemens Healthineers, Medtronic, GE Healthcare and Accuray are among the key market players.

4/19/2018

The FDA granted Siemens Healthineers clearance for its 128-slice Somatom go.Top and the 64-slice Somatom go.All. The scanners feature the company's Athlon X-ray tube, which allows for individualized dose optimization with voltage that can be adjusted in 10-kilovolt increments and a flexible gantry-mounted injector arm that facilitates contrast injection.

More Summaries:
Siemens Healthineers, FDA
4/19/2018

European regulators granted Beckman Coulter Diagnostics CE mark approval for its DxH 520 hematology analyzer, which improves efficiency and resource management in physician office laboratories through automation of daily tasks. The system uses two aqueous-based cyanide-, azide- and formaldehyde-free reagents for eliminating disposal costs, allowing for less time on lab operations and more time for patient care.

More Summaries:
Beckman Coulter Diagnostics
4/19/2018

A jury determined C.R. Bard should pay $35 million in punitive damages and $33 million in compensatory damages to a woman who said she was injured by the company's vaginal mesh devices. C.R. Bard still faces about 150 more lawsuits in New Jersey and thousands of lawsuits that have been consolidated for consideration before a federal judge in West Virginia.

More Summaries:
C.R. Bard
4/19/2018

Fewer than 25% of kidney disease researchers had consulted patients to gain insight into their needs and preferred outcomes, while 90% of patients and caregivers expressed interest in helping develop research projects, according to the results of a survey of more than 1,500 stakeholders. Moreover, the results of studies are often published in limited-access medical journals inaccessible to most patients, putting them at a disadvantage when it comes to decisions about their care, says Jean Slutsky, chief engagement and dissemination officer at the Patient-Centered Outcomes Research Institute.

4/19/2018

A financing round has pulled in $115 million for BenevolentAI, which uses artificial intelligence to identify new drug candidates and has more than 20 drug candidates in its pipeline for diseases including Parkinson's, glioblastoma and sarcopenia. The firm's technology analyzes scientific research and clinical studies to identify new drug candidates and new uses for existing drugs.

Full Story:
Reuters
More Summaries:
glioblastoma, Parkinson
4/19/2018

Kleiner Perkins General Partner Beth Seidenberg is leading the company's $35 million investment in Tmunity, a University of Pennsylvania spinoff working with university scientists on gene editing technology to develop personalized immunotherapies. Other investors include the Parker Institute for Cancer Immunotherapy, Ping An Ventures, Gilead Sciences, Be The Match BioTherapies, the University of Pennsylvania and Lilly Asia Ventures.

Full Story:
Endpoints News